NYSE$RCUS
Arcus Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter and provided operational highlights.
Arcus Biosciences reported its second quarter 2021 financial results, highlighting the advancement of its clinical-stage molecules and partnerships, particularly with Gilead. The company ended the quarter with $805.1 million in cash and investments, and collaboration revenue was $9.5 million. Net loss for the quarter was $76.0 million.
- All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types.
- AB521, a small molecule HIF-2α inhibitor, expected to enter the clinic in 4Q21.
- Encouraging results were reported from the interim analysis for ARC-7, providing initial validation of domvanalimab combinations.
- The company ended the quarter with $805 million of cash and investments.
Headline financials
Revenue & EPS history
Arcus Biosciences · Revenue · Quarterly
$9.46M
Revenue by segment
Arcus Biosciences · $10M total across 1 segment · Q3 2023
- Other collaboration$10M+1.6%100.0%
Forward guidance
Arcus Biosciences anticipates several milestones in the near future.
Tailwinds
- Results from the interim analysis for ARC-7 are expected to be submitted later this year for a presentation in 4Q21 or in 1H22.
- An opt-in trigger decision by Gilead for the anti-TIGIT program is anticipated by year-end 2021.
- Initiation of PACIFIC-8, in collaboration with AstraZeneca, is anticipated to start in 4Q21.
- Opening of a new arm to evaluate quemli in second-line pancreatic cancer is expected in 3Q21.
- Initiation of clinical development for the HIF-2α inhibitor, AB521, is anticipated to occur in 4Q21.
Headwinds
- The inherent uncertainty associated with the COVID-19 pandemic, including the duration and/or severity of the pandemic and actions by government authorities to contain or slow the spread of the virus
- The inherent uncertainty associated with pharmaceutical product development and clinical trials
- Dependence on the collaboration with Gilead for the successful development and commercialization of investigational products
- Delays in clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials
- The unexpected emergence of adverse events or other undesirable side effects
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.4%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+6.7%
Avg return
30 days after
59%
19 / 32 earnings
Positive
+19.2%
Q4 2021
Best reaction
-7.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -2.6% | -5.6% | |
| Q4 2025 | -4.0% | +10.7% | +0.0% | |
| Q3 2025 | -1.1% | +2.7% | +28.9% | |
| Q1 2025 | -1.2% | +8.4% | +22.8% | |
| Q4 2024 | -1.0% | -7.3% | -18.4% | |
| Q3 2024 | +7.7% | +16.1% | +13.1% | |
| Q2 2024 | +11.5% | +11.7% | +12.3% | |
| Q1 2024 | +3.8% | +10.6% | -0.4% | |
| Q4 2023 | +18.5% | +18.4% | -1.0% | |
| Q3 2023 | +2.8% | -13.0% | +0.4% | |
| Q2 2023 | -3.0% | -4.3% | +18.3% | |
| Q1 2023 | -5.2% | -6.9% | +9.0% | |
| Q4 2022 | -4.0% | +0.6% | -3.7% | |
| Q3 2022 | -2.2% | -7.9% | +43.2% | |
| Q2 2022 | +6.0% | +7.9% | -2.1% | |
| Q1 2022 | +11.9% | -9.7% | +10.1% | |
| Q4 2021 | +19.2% | +24.6% | +20.4% | |
| Q3 2021 | +11.4% | +9.1% | +26.5% | |
| Q2 2021 | -7.3% | -2.5% | +13.7% | |
| Q1 2021 | -7.9% | -11.7% | -23.4% | |
| Q4 2020 | +2.9% | +10.3% | -1.7% | |
| Q3 2020 | -7.1% | +3.8% | +33.1% | |
| Q2 2020 | +2.3% | +8.1% | -1.1% | |
| Q1 2020 | -0.7% | +11.4% | +11.3% | |
| Q4 2019 | +7.1% | -2.6% | -19.8% | |
| Q3 2019 | +1.6% | -6.3% | -3.2% | |
| Q2 2019 | +1.8% | +10.3% | +18.2% | |
| Q1 2019 | +4.9% | +9.1% | -15.5% | |
| Q4 2018 | -6.8% | +11.6% | -3.7% | |
| Q3 2018 | +8.9% | -1.1% | +8.0% | |
| Q2 2018 | +2.2% | +7.5% | +19.0% | |
| Q1 2018 | +2.9% | -1.1% | +6.9% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro